Barclays
PRQR icon

Barclays’s ProQR Therapeutics PRQR Stock Holding History

Barclays’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-22,600
Closed -$20K – 5207
2022
Q1 		$20K Buy
22,600
+22,580
+112,900% +$75.6K ﹤0.01% 4446
2021
Q4 		$0 Sell
20
-3
-13% -$23 ﹤0.01% 4608
2021
Q3 		$0 Sell
23
-12
-34% -$78 ﹤0.01% 4944
2021
Q2 		$0 Hold
35
– – ﹤0.01% 5041
2021
Q1 		$0 Sell
35
-3,153
-99% -$16.1K ﹤0.01% 5092
2020
Q4 		$13K Sell
3,188
-5,800
-65% -$24.5K ﹤0.01% 4728
2020
Q3 		$43K Sell
8,988
-1,500
-14% -$7.84K ﹤0.01% 4668
2020
Q2 		$64K Buy
10,488
+7,135
+213% +$38.5K ﹤0.01% 4805
2020
Q1 		$18K Buy
3,353
+3,003
+858% +$23K ﹤0.01% 5675
2019
Q4 		$4K Sell
350
-1,937
-85% -$15.1K ﹤0.01% 6193
2019
Q3 		$12K Buy
2,287
+204
+10% +$1.63K ﹤0.01% 6318
2019
Q2 		$18K Sell
2,083
-15,370
-88% -$181K ﹤0.01% 6433
2019
Q1 		$243K Buy
17,453
+14,237
+443% +$213K ﹤0.01% 4683
2018
Q4 		$51K Buy
+3,216
New +$59K ﹤0.01% 5467

Other funds holding PRQR

PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
MCM
M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Barclays's PRQR Position: Q2 2022 in Review

Barclays sold out of ProQR Therapeutics (PRQR) in Q2 2022, closing a stake of 22,600 shares — an estimated $20K sold.

Barclays first reported a position in PRQR in Q4 2018 and held it in 14 quarters. The position peaked at $243K in Q1 2019. 51 funds tracked by Wall St. Rank hold PRQR as of Q2 2022.

  • Barclays reported no remaining ProQR Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Barclays sold 22,600 ProQR Therapeutics shares in Q2 2022, an estimated $20K.
  • Barclays first reported a position in ProQR Therapeutics in Q4 2018 and held it in 14 quarters.
  • Barclays's ProQR Therapeutics position peaked at $243K in Q1 2019.
  • 51 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2022.

Based on Barclays's 13F filing for Q2 2022, filed 12 Aug 2022.